Source of business for IL-23 agents in psoriasis varies across biologic brands. Tremfya’s source of business includes a higher proportion of patients who have previously tried an IL-17 agent before starting an IL-23, as compared to Skyrizi. This finding suggests a preference in the market for Tremfya ahead of Skyrizi after a patient switches from an IL-17 agent.
CRA analytics insight
- A higher proportion of Tremfya patients, versus Skyrizi patients, were previously treated with an IL-17 agent (i.e., Cosentyx or Taltz) prior to trying an IL-23
- A higher proportion of Skyrizi patients were previously treated with a TNF agent compared to Tremfya patients
CRA not only uncovers new trends in data, but delves deeper to illuminate the “why” behind the findings. To learn more, contact Eddie Li.
